Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer

Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer

KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional releva...

Full description

Bibliographic Details
Main Authors: Masayuki Hiraki, Junichi Nishimura, Hidekazu Takahashi, Xin Wu, Yusuke Takahashi, Masaaki Miyo, Naohiro Nishida, Mamoru Uemura, Taishi Hata, Ichiro Takemasa, Tsunekazu Mizushima, Jae-Won Soh, Yuichiro Doki, Masaki Mori, Hirofumi Yamamoto
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
AKT
colorectal cancer
KRAS
microRNA
miR-4689
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253116300178

Internet

http://www.sciencedirect.com/science/article/pii/S2162253116300178

Similar Items